Sputnik V (Gam-COVID-Vac) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
RESIST (Sputnik V Gamaleya Research Institute Russia) NCT04530396		RCT	Sputnik V (Gam-COVID-Vac)	placebo	COVID-19 prophylaxis (excluding children)	high	16501/5476	suggested	suggested 73 % decrease in confirmed Covid-19, from 1st dose but with a low degree of certainty due to high risk of bias suggested 92 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis